Clinical Trial Update: Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating cobimetinib in combination with atezolizumab in participants with advanced or refractory rare tumors. Results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Appendiceal Adenocarcinoma
• Skin Squamous Cell Carcinoma
• Small Intestinal Adenocarcinoma
• Squamous Cell Carcinoma of the Skin

Drugs mentioned

• Cotellic (cobimetinib)
• Tecentriq (atezolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-05-28